Abstract
Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib resistance, including dose escalation of the drug, combination treatments or novel targeted agents. Nilotinib is a second-generation tyrosine kinase inhibitor 30-50 fold more potent than imatinib with high affinity and selectivity on BCR/ABL, active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients; front-line treatment of chronic phase Ph+ CML demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials.
Current Drug Targets
Title: Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL
Volume: 10 Issue: 6
Author(s): Massimo Breccia and Giuliana Alimena
Affiliation:
Abstract: Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib resistance, including dose escalation of the drug, combination treatments or novel targeted agents. Nilotinib is a second-generation tyrosine kinase inhibitor 30-50 fold more potent than imatinib with high affinity and selectivity on BCR/ABL, active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients; front-line treatment of chronic phase Ph+ CML demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials.
Export Options
About this article
Cite this article as:
Breccia Massimo and Alimena Giuliana, Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL, Current Drug Targets 2009; 10 (6) . https://dx.doi.org/10.2174/138945009788488468
DOI https://dx.doi.org/10.2174/138945009788488468 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research Adrenomedullin-RAMP2 System in Cardiovascular Development and Homeostasis
Current Hypertension Reviews Supraventricular Tachycardia in Fetus: How Can We Treat ?
Current Pharmaceutical Design Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Preface
Current Medical Imaging The Role of Point of Care Ultrasound in the Injured Paediatric Patient
Current Pediatric Reviews Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry The Role for Adjunctive Image in Pre-procedural Assessment and Peri-Procedural Management in Chronic Total Occlusion Recanalisation
Current Cardiology Reviews The Use of Echocardiography in the Critically Ill; The Role of FADE (Fast Assessment Diagnostic Echocardiography) Training
Current Cardiology Reviews Pathogenesis of HIV-Associated Non-Hodgkin Lymphoma
Current HIV Research What’s Old is New Again – A Review of the Current Evidence of Colchicine in Cardiovascular Medicine
Current Cardiology Reviews Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry